Abstract 1483
Background
Sodium alginate, which has been approved for treatment of gastritis in Japan, is highly viscous and thus remains in the esophageal mucosa for long periods, leading to a protective effect in the esophagus. The purpose of this trial was to investigate whether sodium alginate has a substantial preventive effect on severe esophagitis in pts with non-small-cell lung cancer (NSCLC) receiving concurrent chemoradiotherapy (CRT).
Methods
Patients with untreated stage III NSCLC who were eligible for concurrent CRT were randomly assigned at a 1:1:1 ratio to receive one of the following treatments: sodium alginate administered concomitantly with CRT (A), sodium alginate administered soon after development of extremely mild esophagitis during CRT (B), or water administered with CRT (C). The primary endpoint was the proportion of pts with G3 or higher severe esophagitis (CTCAE ver. 4.0).
Results
Ninety-four patients were randomly assigned to the three treatment arms between Feb 2014 and Sep 2018. The study was prematurely terminated in Oct 2018 because of slow accrual. The proportion (95% confidence interval) of patients with G3 or more severe esophagitis was 12.5% (3.5–29.0%) in arm A, 9.8% (2.0–25.8%) in arm B, and 19.4% (7.5–37.5%) in arm C. Fewer patients receiving sodium alginate had onset of G3 esophagitis, but the differences compared with arm C were not significant (A v C: p = 0.46; B v C: p = 0.28). The rate of non-hematologic toxicities other than esophagitis was 29% in arm A, 26% in arm B, and 43% in arm C. Of note, early use (arm A) but not late use (arm B) of sodium alginate resulted in a significantly lower rate of febrile neutropenia (FN) compared with arm C (A v C: 3.1% v 19.4%, p = 0.04; B v C: 6.5% v 19.4%, p = 0.13). The 2-year progression-free and overall survival rates were 36% and 78% in arm A, 52% and 90% in arm B, and 61% and 75% in arm C, respectively.
Conclusions
Sodium alginate did not show a significant preventative effect on radiation-induced severe esophagitis in patients with NSCLC. However, its early use resulted in a lower rate of FN onset induced by CRT, suggesting that esophageal mucosal protection by sodium alginate may suppress FN.
Clinical trial identification
UMIN 000013113.
Editorial acknowledgement
Legal entity responsible for the study
Okayama Lung Cancer Study Group.
Funding
Has not received any funding.
Disclosure
T. Yokoyama: Honoraria (self): Chugai Pharmaceutical co ltd; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): MSD KK; Honoraria (self): AstraZeneca; Honoraria (self): Ono Pharmaceutical co Ltd. K. Ninomiya: Honoraria (self): Lilly Japan; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): AstraZeneca; Honoraria (self): Ono Pharmaceutical co ltd; Honoraria (self): Chugai Pharmaceutical co ltd; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): MSD KK. A. Bessho: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self), Research grant / Funding (self): Pfizer; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Astellas Pharma; Honoraria (self): Novartis; Research grant / Funding (self): Kyorin; Research grant / Funding (self): Amgen; Research grant / Funding (self): Taisho Toyama Pharma; Research grant / Funding (self): Bayer Yakuhin. S. Hosokawa: Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self): Ono Pharmaceutical; Honoraria (self): AstraZeneca. T. Kozuki: Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Lilly Japan; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Japan; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): MSD KK; Research grant / Funding (institution): Merck Serono. D. Harada: Honoraria (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): AstraZeneca; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): MSD KK; Honoraria (self): Eli Lilly Japan. T. Murakami: Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): AstraZeneca. N. Takigawa: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Daiichi-Sankyo Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer-Ingelheim; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self): MSD KK; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan; Research grant / Funding (institution): Kyowa Hakko Kirin; Research grant / Funding (institution): Nippon Kayaku. K. Hotta: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer Ingelheim; Honoraria (self): Nippon Kayaku; Honoraria (self): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Japan; Honoraria (self), Research grant / Funding (institution): Lilly Japan; Honoraria (self), Research grant / Funding (institution): MSD KK; Research grant / Funding (institution): Astellas Pharma. K. Kiura: Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Nippon Kayaku; Honoraria (self): Daiichi Sankyo; Honoraria (self): Shionogi; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Lilly Japan. All other authors have declared no conflicts of interest.
Resources from the same session
2023 - Patients with brain metastases treated with afatinib in clinical practice – results from the prospective non-interventional study GIDEON
Presenter: Eckart Laack
Session: Poster Display session 1
Resources:
Abstract
1613 - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results
Presenter: David Berz
Session: Poster Display session 1
Resources:
Abstract
2853 - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
Presenter: Petros Christopoulos
Session: Poster Display session 1
Resources:
Abstract
1974 - A Phase II Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients with Activating Epidermal Growth Factor Receptor mutation (EGFRm) from Circulating Tumor DNA (CtDNA)
Presenter: Young-Chul Kim
Session: Poster Display session 1
Resources:
Abstract
3370 - Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients
Presenter: Geerten Veerman
Session: Poster Display session 1
Resources:
Abstract
5900 - PTEN loss as Predictor of Tumor Heterogeneity (TH) and Poor Prognosis in EGFR-mutant Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients (pts) Receiving Tyrosine-Kinase Inhibitors (TKIs).
Presenter: Miriam Ferrara
Session: Poster Display session 1
Resources:
Abstract
1302 - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
1497 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial
Presenter: Dae Ho Lee
Session: Poster Display session 1
Resources:
Abstract
2349 - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).
Presenter: Kei Kunimasa
Session: Poster Display session 1
Resources:
Abstract
1120 - Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the Use Via Expanded Access to Brigatinib (UVEA-Brig) study
Presenter: Silvia Novello
Session: Poster Display session 1
Resources:
Abstract